Foghorn therapeutics presents new preclinical data on potential first-in-class brm selective inhibitor fhd-909 and selective cbp and selective ep300 degrader oncology programs

First-in class brm (smarca2) selective inhibitor fhd-909 demonstrated favorable tolerability and dose-dependent single agent activity in brg1 mutated cancers preclinically; ind filing on track for q2 2024
FHTX Ratings Summary
FHTX Quant Ranking